Unlock 30% off global market reports with code ONLINE30 – get insights on tariff changes, macro trends, and global economic shifts.
What are the growth projections for the wilson's disease drugs market from 2024 to 2029?
The wilson's disease drugs market size has grown strongly in recent years. It will grow from $0.62 billion in 2024 to $0.66 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to rising awareness of Wilson’s disease and its symptoms, growth in clinical research, an increase in the availability of standard treatment, rising healthcare infrastructure, and a growing number of diagnosed cases.
The wilson's disease drugs market size is expected to see strong growth in the next few years. It will grow to $0.85 billion in 2029 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to rising investment in novel drug development and gene therapy, increasing adoption of personalized medicine, growth in patient awareness campaigns, increasing healthcare funding, and rising regulatory approvals. Major trends in the forecast period include the development of gene therapy approaches, enhanced use of biomarkers for monitoring disease progression, integration of digital health tools, expansion of orphan drug designations, encouraging investment, and expansion of treatment options through combination therapies.
Download Your Free Sample PDF:
What strategic initiatives by market players are driving wilson's disease drugs industry growth?
The growing incidence of genetic disorders is expected to propel the growth of the wilson's disease drugs market going forward. Genetic disorders are diseases caused by abnormalities in an individual's DNA, either due to mutations, deletions, or chromosome changes. Genetic disorders are increasing mainly due to higher parental age, which raises the risk of inheritable mutations being passed to offspring. Wilson's disease drugs treat the genetic disorder by lowering harmful copper levels caused by ATP7B gene mutations. They achieve this by enhancing copper excretion or blocking its absorption, protecting vital organs such as the liver and brain. For instance, in September 2023, according to the Cystic Fibrosis Trust, a UK-based national charity, in the UK, the number of patients registered with cystic fibrosis was 11,148 in 2022, a significant increase compared to 10,908 in 2021. Therefore, the growing incidence of genetic disorders is driving the growth of the Wilson's disease drugs market.
What emerging segments are shaping the future landscape of the wilson's disease drugs industry?
The wilson's disease drugs market covered in this report is segmented –
1) By Type: Chelating Agents, Zinc Therapy, Liver Transplant, Symptomatic Treatments
2) By Route Of Administration: Oral, Intravenous, Subcutaneous
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels
4) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End-Users
Subsegments:
1) By Chelating Agents: Penicillamine, Trientine, Tetrathiomolybdate, Experimental Chelators
2) By Zinc Therapy: Zinc Acetate, Zinc Gluconate, Zinc Sulfate
3) By Liver Transplant: Orthotopic Liver Transplantation, Living Donor Liver Transplantation, Deceased Donor Liver Transplantation
4) By Symptomatic Treatments: Antipsychotic Medications, Antiepileptic Drugs, Antidepressants, Muscle Relaxants, Anticholinergics
View The Full Market Report:
Which major trends are influencing the growth of the wilson's disease drugs industry?
Major companies operating in the wilson's disease drug market are focusing on developing advanced drugs, such as trientine tetrahydrochloride (TETA-4HCl)-based formulations, to enhance treatment outcomes and patient convenience in managing rare diseases. A trientine tetrahydrochloride (TETA-4HCl)-based formulation refers to an advanced oral copper-chelating therapy specifically designed to maintain copper balance in adult patients with stable wilson disease. For instance, in April 2023, Orphalan SA, a France-based orphan drug development and commercialization company, launched Cuvrior. It was approved by the Food and Drug Administration (FDA) and granted Orphan Drug Exclusivity. It is a new trientine tetrahydrochloride (TETA-4HCl) intended for adults with stable wilson disease who are already decoppered and tolerant to penicillamine. It offers a room temperature-stable oral therapy that provides dosing flexibility and convenience compared to previous treatments.
How are key players in the wilson's disease drugs market strengthening their market position?
Major companies operating in the wilson's disease drugs market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Intas Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories, Lupin Pharmaceuticals, Ultragenyx Pharmaceutical Inc., Taj Pharmaceutical Limited, Biophore Pharma Inc., Orphalan SA, Nobelpharma Co. Ltd, Eton Pharmaceuticals, LogicBio Therapeutics, DepYmed, Vivet Therapeutics, Telomir Pharmaceuticals Inc., Innorna.
Which geographic areas are contributing significantly to the growth of the wilson's disease drugs sector?
North America was the largest region in the wilson's disease drugs market in 2024. The regions covered in the wilson's disease drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Wilson's Disease Drugs Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
Need Customized Data On Wilson's Disease Drugs Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you're entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment